Clinical trial
A Phase 1, Open-Label Study Comparing the Safety, Tolerability, and Pharmacokinetics of Single-Dose Intravenous Sabirnetug (ACU193) and Multiple-Dose Subcutaneous Sabirnetug (ACU193) + rHuPH20 in Healthy Participants
NCT06511570 is registered in ClinicalTrials.gov with Acumen Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label Study Comparing the Safety, Tolerability, and Pharmacokinetics of Single-Dose Intravenous Sabirnetug (ACU193) and Multiple-Dose Subcutaneous Sabirnetug (ACU193) + rHuPH20 in Healthy Participants
- Lead sponsor
- Acumen Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 25, 2024
- Completion date
- September 17, 2024
- Enrollment
- 28 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.